Skip to main content
Feedback to SSRN
Feedback
(required)
Email
(required)
Submit
COVE Study Group
United States
Learn more about SSRN Profiles
SCHOLARLY PAPERS
1
DOWNLOADS
127
TOTAL CITATIONS
0
Feedback
Scholarly Papers (1)
Sort by:
Paper Title, A-Z
Paper Title, Z-A
Author Name, A-Z
Author Name, Z-A
Date Posted, Ascending
Date Posted, Descending
Downloads, Ascending
Downloads, Descending
Citations, Ascending
Citations, Descending
Actions:
Email selected abstracts
View:
Selected
Original List
All Versions
Hide All Versions
All Abstracts
Hide All Abstracts
(Rank)
1.
Immunogenicity of the mRNA-1273 Vaccine in the Phase 3 COVE Trial
Number of pages: 40
Posted: 29 Dec 2021
Hana M. El Sahly
,
Lindsey Baden
,
Brandon Essink
,
David C. Montefiori
,
Adrian McDermont
,
Richard Rupp
,
Michael Lewis
,
Shobha Swaminathan
,
Carl Griffin
,
Veronica Fragoso
,
Vicki E. Miller
,
Bethany Girard
,
Yamuna D. Paila
,
Weiping Deng
,
Joanne E. Tomassini
,
Robert Paris
,
Florian Schodel
,
Rituparna Das
,
Alison August
,
Brett Leav
,
Jacqueline M. Miller
,
Honghong Zhou
,
Rolando Pajon
and COVE Study Group
Baylor College of Medicine, Harvard University - Brigham and Women’s Hospital, Meridian Clinical Research, Duke University - Duke Human Vaccine Institute, Government of the United States of America - Vaccine Research Center, University of Texas Medical Branch-Galveston - The Sealy Institute for Vaccine Sciences, Government of the United States of America - VA Greater Los Angeles Healthcare System (GLA), Rutgers, The State University of New Jersey - New Jersey Medical School, Lynn Health Science Institute (Lynn Institute), DM Clinical Research - Texas Center for Drug Development (TCDD), DM Clinical Research, Moderna, Inc., Moderna, Inc., Moderna, Inc., Moderna, Inc., Moderna, Inc., Moderna, Inc., Moderna, Inc., Moderna, Inc., Moderna, Inc., Moderna, Inc., Moderna, Inc., Moderna, Inc. and Independent
Downloads
127
(572,948)
View PDF
Download
Abstract:
mRNA-1273, immunogenicity, antibodies, SARS-CoV-2, vaccine
Feedback